Nucleotide-binding oligomerization domain-like receptor protein 3 inflammasomes and associated pathways in schizophrenia: potential as therapeutic targets
10.3760/cma.j.cn113661-20230925-00094
- VernacularTitle:核苷酸结合寡聚化结构域样受体蛋白3炎症小体及相关通路在精神分裂症中的作用及作为治疗靶点的潜力
- Author:
Yingying ZHANG
1
;
Haoran XING
;
Xi ZHANG
;
Qing YUAN
;
Mier LI
;
Yuan YE
;
Tianhao BAO
Author Information
1. 昆明医科大学附属精神卫生中心科教科，昆明 650224
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Models, animal;
Antipsychotic Agents;
Neuroinflammation;
NLRP3
- From:
Chinese Journal of Psychiatry
2024;57(7):419-425
- CountryChina
- Language:Chinese
-
Abstract:
Recent studies have revealed a strong association between the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome and its associated pathways and neuroinflammation in schizophrenia. The activation of the NLRP3-inflammasome and aberrations in its associated pathways may be related to a certain extent to the psychotic symptoms of schizophrenia, neurotransmission dysfunction, impaired prepulse inhibition, and behavioural deficits observed in schizophrenic patients. A variety of antipsychotics can ameliorate neuroinflammation in schizophrenia by inhibiting NLRP3 inflammatory vesicles or blocking their associated pathways. This article summarizes and discusses the research findings related to NLRP3 inflammatory vesicles and their pathways in schizophrenic patients and their relevant animal models. It aims to explore the possibility and efficacy of treating schizophrenia by regulating the NLRP3 inflammatory vesicles and associated signaling pathways.
